Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100685 · ClinicalTrials.gov registry record · Phase 2
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00100685: Clinical Trial Phase 2 study, sponsored by Abbott.
NCT00100685 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100685, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Interventions
- DRUG Volociximab (anti-α5β1 integrin monoclonal antibody)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Why NCT00100685 stopped before completion
NCT00100685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which Volociximab (anti-α5β1 integrin monoclonal antibody) is the first listed.
NCT00100685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00100685 about?
NCT00100685 is a clinical study titled "Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)". This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
What is the current status of trial NCT00100685?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00100685?
The interventions under investigation include: Volociximab (anti-α5β1 integrin monoclonal antibody) (DRUG).
Who is sponsoring clinical trial NCT00100685?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00100685's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia